In a major stride towards revolutionizing leukemia treatment in the U.S., Cycle Pharmaceuticals has signed an exclusive sales license agreement with Handa Therapeutics LLC for the commercialization of PHYRAGO (dasatinib tablets). This collaboration marks Cycle’s official entry into the oncology segment, expanding its portfolio of specialized treatments for patients with chronic conditions.
PHYRAGO is a FDA-approved therapy designed to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). With this strategic partnership, Cycle Pharmaceuticals will lead the U.S. sales and distribution efforts, while both companies work in synergy to optimize patient support and market expansion.
What Makes PHYRAGO a Game-Changer?
PHYRAGO is a novel formulation of Sprycel (dasatinib), purpose-built to address a long-standing clinical gap: the inability to co-administer dasatinib with proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs). Unlike traditional dasatinib therapies, PHYRAGO maintains its bioavailability even when used alongside these commonly prescribed medications, improving both treatment flexibility and patient outcomes.
Studies have shown a 40 60% reduction in dasatinib’s effectiveness when used with H2RAs and PPIs. However, PHYRAGO eliminates this risk, offering seamless integration into existing treatment plans.
PHYRAGO also includes important safety guidelines around fluid retention, myelosuppression, bleeding events, cardiovascular toxicity, QT prolongation, tumor lysis syndrome, dermatologic reactions, and risks associated with pediatric use, pregnancy, and lactation. Full prescribing information can be accessed at www.phyrago.com/PI/.
Launch and Support Coming September 2025
The official U.S. launch of PHYRAGO is scheduled for September 2025. Patients will also benefit from Cycle Vita, Cycle Pharmaceuticals’ personalized support platform that offers educational resources, financial assistance, and product guidance tailored for adult patients with Ph+ALL and Ph+CML.
Leadership Speaks: A Unified Vision for Better Cancer Care
Bill Liu, President and CEO of Handa Therapeutics, shared his enthusiasm:
“We are thrilled to announce our second collaboration with Cycle and to bring PHYRAGO to leukemia patients across the U.S. This is not just a product launch it’s a promise to elevate patient care in oncology. PHYRAGO, with Cycle Vita’s robust support program, will set new standards in individualized cancer care.”
This collaboration reflects both companies’ shared mission: to bring advanced, quality treatments to patients who need them most.
Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com
